How Trump's 2025–2026 Tariffs Are Hitting Prescription Drugs and Medical Devices

Overview: A Partial Exemption That's Slowly Eroding

When the Trump administration launched its sweeping IEEPA tariff regime in April 2025, pharmaceuticals and medical devices were among the sectors that received explicit carve-outs. Finished drug formulations under HTS Chapter 30 — the bottles of pills, vials of insulin, and blister-packed generics that fill US pharmacy shelves — were initially excluded from the most punishing tariff layers. The rationale was straightforward: a 145% tariff on Chinese pharmaceuticals would cause immediate, visible harm to American patients and was politically untenable.

But the exemption was never as comprehensive as the industry hoped. Active pharmaceutical ingredients — the chemical compounds that make drugs work — were not consistently protected. Medical devices fell into a murky middle ground where some categories received explicit protection while others were swept into Section 301 lists or the universal 10% baseline. And crucially, the administration has signaled repeatedly that pharmaceutical exemptions may be revisited in 2026 on national security grounds, citing US overdependence on Chinese and Indian drug manufacturing as a strategic vulnerability.

The result is a sector navigating an unstable tariff landscape where yesterday's exemption may not be tomorrow's reality — and where the supply chain complexity makes calculating true landed cost far harder than in simpler import categories.

Active Pharmaceutical Ingredients: The Unprotected Core

Active pharmaceutical ingredients are the chemical foundation of every drug — the molecule that actually treats disease. APIs are classified primarily under HTS Chapter 29 (organic chemicals), not Chapter 30 (pharmaceutical preparations). This distinction is critical: while finished drugs under Chapter 30 received exemptions in most IEEPA and Section 301 rounds, Chapter 29 chemicals did not receive the same protection.

The geographic concentration of API supply is staggering. Over 80% of APIs used in US-marketed drugs — across both branded and generic categories — are manufactured in China or India, or rely on Chinese intermediates at some point in the synthesis chain. For specific therapeutic categories, the concentration is even higher: antibiotics, blood pressure medications, diabetes treatments, psychiatric drugs, and cancer generics are heavily dependent on Chinese API manufacturing. Subheading 2941.xx (antibiotics) and 2936.xx (vitamins) are among the most China-concentrated HTS codes in pharmaceutical trade.

Under the current tariff structure, Chinese-origin APIs classified under Chapter 29 face: the applicable MFN rate (typically 0%–6.5%) plus Section 301 tariffs that range from 7.5% to 25% depending on which list the specific chemical appears on, plus the 10% universal baseline from the Section 122 action. On many antibiotics and common generic APIs, the effective rate from China is now 35%–40% — an enormous cost increase in a market where generic drug pricing is already razor-thin and determined by competitive bidding.

For US generic drug manufacturers — the companies that buy APIs and turn them into finished tablets and capsules — this creates a structural margin problem. Generic drug prices are set by pharmacy benefit managers and formulary negotiations, not by import cost. A generic API that costs 35% more to import cannot simply be repriced at the pharmacy counter to compensate. The result is accelerating generic drug shortages in categories where all the economics have been destroyed by tariff-induced cost inflation.

Indian API manufacturers supply a significant portion of the intermediates used in Chinese API production, and Indian finished API exports to the US also face the 26% reciprocal tariff framework — addressed further in Section 5 below. The dual exposure — Chinese API tariffs plus Indian API tariff risk — means there is no clean supply chain pivot available at scale.

Importers dealing in pharmaceutical chemicals should review their Chapter 29 entries against the duty drawback program for any exported or destroyed API inventory. For manufacturers that import APIs and export finished drugs, manufacturing drawback under 19 U.S.C. § 1313(a) can recover up to 99% of duties paid.

Medical Devices (HTS Chapter 90): What's Hit and How Hard

Medical devices are classified under HTS Chapter 90 — optical, photographic, measuring, and medical instruments. Unlike pharmaceuticals, medical devices did not receive broad exemptions from Section 301 tariffs; many categories were included on the lists as far back as 2018–2019 and remain subject to tariffs today, layered with the universal 10% Section 122 surcharge.

China is the dominant source for the commodity end of the medical device spectrum: disposable surgical tools, syringes and needles (HTS 9018.31–9018.39), catheters, blood pressure cuffs, wound care products, and examination gloves. It is also a major source of capital equipment components — imaging system subassemblies, ultrasound transducer components, hospital monitor displays, and MRI coil assemblies enter the US under HTS 9018.12 (ultrasound), 9022.12 (CT scanners), and related subheadings.

Medical Device & Pharma HTS Codes: Effective Tariff Rates by Country (2026)

The table below shows representative HTS codes for pharmaceuticals and medical devices, with MFN baseline rates and effective 2026 rates by key country of origin. China rates reflect MFN + Section 301 + Section 122 post-IEEPA. India rates reflect MFN + 26% reciprocal tariff where applicable.

*Finished drug (Chapter 30) exemptions are by executive order and subject to revocation. India reciprocal tariff applies if exemptions are removed. Rates are approximate; always verify against current CBP CROSS rulings.

Hospital Supply Chain Pass-Through: How Tariff Costs Reach Patients

Unlike consumer goods where tariff cost increases translate relatively quickly to retail shelf prices, the healthcare supply chain has structural friction that delays — but does not prevent — pass-through to patients and insurers.

The chain begins at the importer of record: typically a device manufacturer's US subsidiary, a pharma distributor, or a specialty importer that clears goods at the port and pays duties immediately. These entities absorb the tariff cost in their landed cost calculations. For high-volume commodity products (syringes, IV bags, sutures), the tariff burden may be immediately visible in gross margins. For capital equipment (MRI machines, imaging systems), the tariff is embedded in multi-year supply contracts that can't be easily renegotiated.

The next layer is the distributor or Group Purchasing Organization (GPO). Major healthcare distributors — which service hospitals under long-term contracts with fixed pricing provisions — typically absorb tariff cost increases for 6–18 months before triggering contract renegotiations. The leverage dynamic is complex: hospitals can't easily switch distributors mid-contract, but distributors also can't indefinitely absorb tariff-driven cost inflation. GPOs, which aggregate purchasing across hundreds of hospital members, are beginning to receive formal tariff surcharge notifications from device and supply manufacturers.

Hospitals and health systems represent the next level of absorption. Hospital supply chain budgets are already under pressure from labor cost inflation and volume normalization post-COVID. A 25–35% increase in the landed cost of Chinese-origin surgical disposables — which represent a large share of the ~$100 billion annual hospital supply market — creates a direct operating cost problem that flows directly into hospital EBITDA margins. Non-profit health systems have limited ability to reprice services quickly; commercial systems may accelerate insurer contract renegotiations.

At the end of the chain, insurers face higher claims costs — eventually — and pass those through via premium increases, higher deductibles, or narrower formularies. Individual patients experience the tariff impact most visibly when their insurer changes formulary coverage for generics (typically in annual benefit resets) or when cost-sharing for specific treatments increases at renewal.

Use the refund impact estimator to model how tariff costs affect your specific import categories — the tool handles Chapter 29, 30, and 90 classifications.

India API Risk: 40% of US Generics in the Crosshairs

India's role in the US pharmaceutical supply chain is enormous and often underappreciated. Indian pharmaceutical manufacturers supply approximately 40% of all generic drugs sold in the United States by volume, and Indian facilities are approved by the FDA at a rate second only to the US itself. Drugs treating chronic conditions — diabetes (metformin, glipizide), hypertension (lisinopril, amlodipine), high cholesterol (atorvastatin), depression (sertraline), and pain (ibuprofen, naproxen) — are overwhelmingly sourced from Indian generics manufacturers.

India's tariff exposure runs in two directions. First, India itself was assessed at 26% under the Trump reciprocal tariff framework — a rate based on the administration's calculation of Indian trade barriers against US goods. If the current exemption on finished pharmaceutical products (Chapter 30) is removed, Indian-origin generic drugs would face a 26% duty that would be catastrophic for the generic drug market. A drug like generic metformin — which sells at the pharmacy for $4–$10 per month — cannot sustain a 26% import duty without either disappearing from the market or dramatically increasing in price.

Second, Indian pharma manufacturers are themselves heavily dependent on Chinese APIs and chemical intermediates. India imports 60–70% of its pharmaceutical raw materials from China. The Section 301 tariffs on Chinese APIs increase costs for Indian manufacturers — costs that eventually flow through to the US importer in the form of higher invoice prices, even if the Indian finished drug technically avoids direct US tariff exposure. This indirect pass-through is already visible in generic drug tender pricing revisions.

Vietnam is sometimes mentioned as an alternative to Indian API and generics manufacturing — but Vietnam's pharmaceutical sector is early-stage, and the 46% reciprocal tariff the US assessed on Vietnam actually makes Vietnamese-origin drugs more expensive to import than Indian goods even at the 26% India rate. The counterintuitive math: Vietnam's tariff rate (46%) exceeds China's effective post-IEEPA rate (35%) and India's reciprocal tariff (26%) for most pharmaceutical categories, making it the worst alternative from a tariff-cost perspective despite its "China alternative" reputation in other sectors.

Ireland remains the preferred jurisdiction for branded pharmaceutical manufacturing targeted at the US market — Irish facilities have long served as the manufacturing base for blockbuster drugs due to favorable tax treatment and access to EU regulatory systems. Ireland faces only the 10% universal baseline tariff from the Section 122 action, with no additional Section 301 or reciprocal tariff exposure. For generic manufacturers, Malaysia and Singapore offer comparable tariff advantages (~10–13.7%) with functional pharmaceutical manufacturing infrastructure — though building out API supply chains takes years, not months.

Current Exemption Status: What's Protected, What's at Risk, 2026 Timeline

As of early 2026, the pharmaceutical tariff exemption landscape breaks down roughly as follows:

• Finished pharmaceutical formulations (HTS 3002–3006): Generally exempt from IEEPA surcharges and most Section 301 tariffs via executive order carve-out. The universal 10% Section 122 baseline applies in some interpretations. This exemption is maintained by executive discretion and could be revoked; the administration has stated it is reviewing pharmaceutical tariff policy as part of its national security supply chain review. Status: Conditional exemption, at risk for removal in 2026.
• Active pharmaceutical ingredients (HTS Chapter 29): No blanket exemption. Subject to Section 301 tariffs (7.5%–25%) and the universal 10% baseline. China-origin APIs are currently dutiable. Indian-origin APIs face the 26% reciprocal tariff framework if exemptions are removed. Status: Actively taxed. No relief currently available via exemption.
• Medical devices — capital equipment (HTS 9018.12, 9022.12, 9022.21): Imaging systems (CT, MRI, ultrasound) face Section 301 tariffs at 0–7.5% plus 10% universal surcharge. Many high-value imaging components were on earlier exclusion lists that have expired. Status: Tariffs apply; expired exclusions have not been renewed in most categories.
• Medical devices — disposables (HTS 9018.31–9018.39): Syringes, needles, catheters, and surgical disposables from China face Section 301 at 7.5%–25% plus universal surcharge, resulting in effective rates of 17.5%–35%. Status: Tariffs apply at meaningful rates; no current exemption path.
• PPE and respiratory equipment (HTS 9020, 6307.90): Personal protective equipment — masks, gloves, gowns — faces full tariff exposure, including the Section 301 China list tariffs and IEEPA during the surcharge period. Gloves (HTS 4015.12) had separate trade remedy actions in addition to Section 301. Status: Fully dutiable; some prior COVID-era exclusions have expired.

The 2026 policy risk is concentrated in two areas: (1) removal of finished drug exemptions under the national security pharmaceutical review, potentially in Q2–Q3 2026; and (2) implementation of the India reciprocal tariff at the 26% assessed rate, which has been suspended pending negotiations but not eliminated. The broader 2025 tariff timeline provides context on how these actions are sequenced.

What Pharmaceutical & Device Importers Can Do Now

The combination of current tariffs on APIs and devices, plus the risk of losing finished drug exemptions, means the window for proactive response is open — but narrowing. Here are the primary mechanisms available:

1. Duty Drawback (Chapter 98 / 19 U.S.C. § 1313)

Duty drawback allows recovery of up to 99% of customs duties on imported goods that are subsequently exported or destroyed. For pharmaceutical importers, the most applicable forms are:

• • Unused merchandise drawback (§ 1313(j)): For APIs or finished drugs imported and then re-exported without processing — for example, overstock sold to international distributors, recalled batches destroyed under FDA supervision, or expired inventory exported to markets with different shelf-life requirements.
• • Manufacturing drawback (§ 1313(a)): For CMOs (contract manufacturers) that import APIs and export finished drug products — covers duties paid on the API component of exported finished goods. Requires detailed Bill of Materials documentation.
• • Substitution drawback: Where imported and domestically sourced APIs of the same commercial grade are interchangeable, substitution drawback allows duties paid on imports to be recovered against exports of domestically-produced equivalents.

2. First Sale Valuation

Most pharmaceutical imports are valued for customs purposes at the "transaction value" — the price the US importer paid the exporter. However, when a multi-tier distribution chain exists (manufacturer → trading company → US importer), first sale valuation allows duties to be assessed on the lower manufacturer-to-trading-company price rather than the trading-company-to-importer price. For branded drug active ingredients where significant marketing and distribution margins are embedded in invoice prices, first sale valuation can reduce the dutiable value by 10–25%, with proportional tariff savings. This requires proactive customs broker engagement and documentation of the underlying supply chain.

3. Foreign Trade Zones and Bonded Warehouses

Foreign Trade Zones (FTZs) allow pharmaceutical importers to defer duty payment until goods enter US commerce, and in some cases to apply tariffs at the lower of the raw material or finished product rate (inverted tariff relief). For APIs that are further processed in the US, FTZ activation entry can be advantageous. Bonded warehouses similarly allow duty deferral — particularly useful for managing cash flow when large API lots are imported in bulk but released to production over time. Importers who anticipate that exemptions will be restored or reduced can warehouse goods duty-paid in-bond, avoiding the need to seek post-entry protests retroactively.

4. CBP Exclusion and Protest Filings

Product-specific exclusion requests remain available under the Section 301 framework for devices and APIs where no domestic alternative exists and the tariff creates documented supply disruption. The USTR exclusion process has been inconsistent, but medical and pharmaceutical applications — particularly where the FDA has designated specific products as medically necessary — have historically received favorable treatment. For entries already liquidated, CBP Form 19 protests can be filed within 180 days of liquidation to challenge the tariff classification or assert exclusion eligibility retroactively.

5. Supply Chain Restructuring

For API sourcing, the medium-term response is supplier diversification away from pure China dependence. Indian API manufacturers remain the most viable near-term alternative for most compound classes — with the caveat that India faces its own tariff risk. Malaysia and Singapore are emerging as credible alternatives for select API categories, with lower tariff exposure (~10–13.7%) and growing pharmaceutical manufacturing capacity. Ireland and the EU remain the preferred jurisdictions for complex biologics manufacturing. The key constraint is that API manufacturing qualification — getting a new supplier through FDA Drug Master File submission and approval — typically takes 18–36 months and cannot be accelerated to respond to a tariff timeline.

Frequently Asked Questions